ENVB Enveric Biosciences, Inc.
$1.47▲ +3.52%
Healthcare
Other
After hours
$1.46▼ -0.68%
Oct 28, 6:53 PM ET
Volume 19.2K
Avg Volume (10D) 50.9K
Key Metrics & Fundamentals
Market Cap
$6.58M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.17 - 13.25
% vs 50 MA
1.39%
% vs 200 MA
-28.11%
RSI-14
52.3
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.23
Free Cash Flow
-$2.44M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$2.99M
COGS
–
Operating Exp
$3.03M
Operating Income
-$3.03M
EBIT
-$3.03M
Pretax Income
-$3.03M
Net Income
-$3.03M
EPS (Diluted)
-0.76
Price & Volume History
Loading chart…
Recent News
Enveric Biosciences Reports Favorable Preclinical Results for Non-Hallucinogenic Psychiatric Candidate
Benzinga · Oct 21, 2026 8:01 AM ET
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
Business Wire · Oct 21, 2026 8:00 AM ET
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Business Wire · Sep 15, 2026 8:00 AM ET
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
Business Wire · Sep 1, 2026 8:30 AM ET
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
Business Wire · Aug 14, 2026 4:05 PM ET
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
Business Wire · Aug 5, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ENVB's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.